Morgan Stanley lowered its price target for Immunocore Holdings to $42.00 per share.

Nov 14, 2026, 4:04 AM ETOpinionRead the original at moomoo.com

Neutral

Morgan Stanley cut its target from $43 per share to $42 per share but kept Equal-Weight. The report adds no company results or business changes, so it does not change Immunocore's outlook.

IMCR · Immunocore Holdings plc

AI read · Neutral

The AI's read

The update changes Morgan Stanley's view of the shares, not Immunocore's reported business. The report gives no new company results or business changes, and the firm kept its rating. So it does not show a change in the company's outlook.

Get alerts for IMCR

Follow Immunocore Holdings plc (IMCR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMCR

Free on the App Store and Google Play, or on the web.